Abstract:The emergence of drug resistance is a recurrent theme in targeted cancer therapies; thus, the understanding and conquering of drug resistance have become focal points in precision cancer medicine. While the biochemical and genetic mechanisms underlying drug resistance are diverse and complex, the state-of-art technologies (high-throughput sequencing, functional genomics, model systems, etc.) leading to the understanding of such mechanisms have been a consistent force driving the advancement of this field. Although many genes have been found to impact drug resistance, the limited convergence from multiple studies indicates that we are still at the beginning stage of unearthing the entire drug-resistance repertoire. New genomic technologies, preclinical models, and computational methodologies are poised to further accelerate the development of this new field. A major obstacle in precision cancer medicine is the inevitable resistance to targeted therapies. Tremendous effort and progress has been made over the past few years to understand the biochemical and genetic mechanisms underlying drug resistance, with the goal to eventually overcome such daunting challenges. Diverse mechanisms, such as secondary mutations, oncogene bypass, and epigenetic alterations, can all lead to drug resistance, and the number of known involved genes is growing rapidly, thus providing many possibilities to overcome resistance. The finding of these mechanisms and genes invariably requires the application of genomic and functional genomic approaches to tumors or cancer models. In this review, we briefly highlight the major drug-resistance mechanisms known today, and then focus primarily on the technological approaches leading to the advancement of this field. A major obstacle in precision cancer medicine is the inevitable resistance to targeted therapies. Tremendous effort and progress has been made over the past few years to understand the biochemical and genetic mechanisms underlying drug resistance, with the goal to eventually overcome such daunting challenges. Diverse mechanisms, such as secondary mutations, oncogene bypass, and epigenetic alterations, can all lead to drug resistance, and the number of known involved genes is growing rapidly, thus providing many possibilities to overcome resistance. The finding of these mechanisms and genes invariably requires the application of genomic and functional genomic approaches to tumors or cancer models. In this review, we briefly highlight the major drug-resistance mechanisms known today, and then focus primarily on the technological approaches leading to the advancement of this field. the CRISPR-Cas system functions as an adaptive immune system in bacteria and has been adapted to engineer mammalian genomes in an efficient manner. The CRISPR-Cas9 screen has become a powerful functional genetic screening approach suitable for mammalian genetic models, including human cancer cells and mouse models. a human cancer cell line panel established by the NCI Developmental Therapeutics Program to discover novel anticancer drugs; they are frequently studied cancer cell lines. a collection of ORF sequences are introduced into cancer cells through transfection in a multiwell format, and the cells are then exposed to single or combinatory agents before being tested for changes in their viability. an organ-bud grown in vitro, based on stem cells from a particular organ to form a 3D epithelial structure while retaining its tissue identity. a xenograft created when cancerous tissue from a patient's primary tumor is implanted directly into an immunodeficient mouse. These models avoid prior selection in tissue culture and may more closely mimic human cancer compared with cell line-derived xenografts. a member of the protein tyrosine kinases family, containing high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. similar to an ORF screen, but with the ORF libraries replaced by siRNA or shRNA libraries. a situation in which cells can tolerate the loss of one of two genes but their simultaneous inactivation causes lethality. Chemical synthetic lethality screens, drug enhancer screens, or ‘drop out’ screens are all intended to identify ways to achieve synthetic lethality. small-molecule drugs that inhibit tyrosine kinases. Tyrosine kinases are enzymes responsible for the activation of many proteins that can be regulated by phosphorylation in signal transduction cascades.

Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens

A comprehensive clinically informed map of dependencies in cancer cells and framework for target prioritization

Functional genomic landscape of T-cell mediated cytotoxicity.

Drug mechanism‐of‐action discovery through the integration of pharmacological and CRISPR screens

Genetic and Pharmacological Interrogation of Cancer Vulnerability Using a Multiplexed Cell Line Screening Platform

Target identification of small molecules using large-scale CRISPR-Cas mutagenesis scanning of essential genes

Abstract 2500: Technical feasibility of CRISPR-based functional profiling for solid tumor precision medicine

Use of CRISPR-based screens to identify mechanisms of chemotherapy resistance

Partial gene suppression improves identification of cancer vulnerabilities when CRISPR-Cas9 knockout is pan-lethal

CRISPR Screens in Synthetic Lethality and Combinatorial Therapies for Cancer

Computational correction of copy-number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells

Arrayed CRISPR/Cas9 Screening for the Functional Validation of Cancer Genetic Dependencies

Functional Precision Medicine Identifies Novel Druggable Targets and Therapeutic Options in Head and Neck Cancer

Abstract 2944: A high-throughput screening system for identifying therapeutic targets in immuno-oncology

Base editing screens define the genetic landscape of cancer drug resistance mechanisms

A preclinical platform for assessing antitumor effects and systemic toxicities of cancer drug targets

Understanding the Genetic Mechanisms of Cancer Drug Resistance Using Genomic Approaches

Abstract PR014: Combinatorial genetic screens to map synthetic lethal interactions and identify new cancer drug targets in KRAS mutant cancers

CRISPR Screen in Mechanism and Target Discovery for Cancer Immunotherapy

Evolution of Molecular Targeted Cancer Therapy: Mechanisms of Drug Resistance and Novel Opportunities Identified by CRISPR-Cas9 Screening

Integrative analysis of CRISPR screening data uncovers new opportunities for optimizing cancer immunotherapy